Q BioMed Inc. has signed an agreement for Strontium89 (Strontium Chloride Sr-89 Injection, USP) to be included on the Federal Supply Schedule (FSS). The agreement provides U.S. veterans and other federal government agencies access to Strontium89 for eligible patients. The FSS contract, effective March 1, has a five-year term and will extend access to Strontium89 to more than nine million VA beneficiaries and others within the federal system.
 
Veterans are at higher risk for prostate, breast, and lung cancer, the three most common cancers treated with Strontium89 for metastatic bone pain.  
 
In the Strontium89 pivotal trial, as many as 79% of patients had pain relief with Strontium89, and twice as many patients treated with Strontium89 had no pain for 3 months compared with placebo. Further, new pain sites were less frequent in patients treated with Strontium89. Strontium89 is administered once every 3 months via injection.
 
“Q BioMed is very encouraged by this important milestone. This agreement further extends the commercial reach of Strontium89 to eligible adult patients suffering pain from metastatic bone cancer in the VA and other federal agencies,” said Q BioMed CEO Denis Corin. “Q BioMed is committed to helping those who serve and have served their country and their families. It is our hope that, through this agreement, we can make a positive impact on the lives of veterans affected by cancer.”